PMA supplement
P030056 S017: ADVIA Centaur HCV, and Atellica HCV
FDA PMA supplement · 30-Day Notice · Siemens Healthcare Diagnostics
Key facts
| Original PMA | P030056 |
|---|---|
| Supplement number | S017 |
| Supplement type | 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | ADVIA Centaur HCV, and Atellica HCV |
| Generic name | Assay, enzyme linked immunosorbent, hepatitis c virus |
| Applicant | Siemens Healthcare Diagnostics |
| Product code | MZO |
| Received date | May 22, 2020 |
| Decision date | Jun 21, 2020 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: